Meet our fourth disruptor Aled Edwards. Discover how Aled and his team at M4K Pharma are using open science to revolutionize how affordable new treatments are discovered and developed. Through collaboration with patient groups, foundations, and educational institutions—along with extensive studies in gene and protein structures—Aled’s team developed small molecule inhibitors designed to target an ultra-rare and fatal form of pediatric cancer called Diffuse Intrinsic Pontine Glioma (DIPG). #thedisruptors

https://bit.ly/3CnjU1P
https://bit.ly/3TmNQBk
https://bit.ly/3cbEeZr